SSY Group Limited

2005

KYG8406X1034

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for SSY Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.75 HKD

Average target price

6.227 HKD

Spread / Average Target

+31.09%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SSY GROUP LIMITED	-3.85%	1.82B
ELI LILLY AND COMPANY	+37.47%	727B
JOHNSON & JOHNSON	-7.84%	354B
MERCK & CO., INC.	+15.65%	328B
ABBVIE INC.	-0.44%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+3.92%	164B
PFIZER, INC.	-1.96%	164B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:39 2024-05-28 EDT			5-day change	1st Jan Change
4.75 ^HKD	-0.84%		-2.06%	-3.85%

12:05pm	SSY Obtains China Approval for Additional Specification, Generic Status of Metabolic Acidosis Drug	MT
05-27	SSY Group Gets China Approval for Chemotherapy-Induced Nausea Treatment	MT

SSY Obtains China Approval for Additional Specification, Generic Status of Metabolic Acidosis Drug	06:05am	MT
SSY Group Gets China Approval for Chemotherapy-Induced Nausea Treatment	05-27	MT
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China	05-27	CI
SSY Group’s Bronchitis Drug Gets Registration Approval in China	05-22	MT
Ssy Group Limited Announces That the Group's Formoterol Fumarate Has Obtained the Approval for Registration from the National Medical Products Administration	05-22	CI
SSY Group Gets Production and Registration Approval for Parkinson’s Disease Drug in China	05-21	MT
Ssy Group Limited Announces That the Group Has Obtained the Approval for Drug Production and Registration for Rasagiline Mesylate Tablets from National Medical Products Administration of China	05-21	CI
SSY Group’s Multiple Electrolytes Injection Passes Chinese Regulator’s Consistency Evaluation	05-13	MT
SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	04-23	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension	04-23	CI
SSY Group Logs Nearly 15% Boost in Q1 Profit	04-16	MT
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	04-08	MT
SSY Group Limited Announces Update on Product Development	04-08	CI
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	04-03	MT
SSY Group Limited Provides Update on Product Development	04-03	CI
SSY Group's Profit Jumps 17% in 2023	03-27	MT
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	03-27	CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
SSY Group Obtains Drug Administration Approval for Diabetes Drug	03-25	MT
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	03-20	MT
SSY Group Limited Announces Update on Product Development	03-20	CI
SSY Group Gets Bulk Drug Approval from Chinese Authorities	03-01	MT
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	03-01	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	02-29	CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	02-29	CI